Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

318.69 +5.28 (+1.69%)

Streaming Delayed Price Updated: 11:03 AM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025

From Instil Bio

Via GlobeNewswire

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

June 09, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case ↗

June 05, 2025

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Via Benzinga

Topics Intellectual Property

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

May 26, 2025

Via Benzinga

3 High-Flying Stocks That Could Soar Even More ↗

May 24, 2025

Via The Motley Fool

Alnylam Issues 2024 Corporate Responsibility Report

May 20, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 12, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

May 08, 2025

Via Benzinga

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 05, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk ↗

May 02, 2025

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.

Via Benzinga

Topics World Trade

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 02, 2025

Via Benzinga

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

May 01, 2025

Via Benzinga

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

May 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗

April 30, 2025

Via The Motley Fool

BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations ↗

April 29, 2025

The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.

Via Investor's Business Daily

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

April 28, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

How Do Investors Really Feel About Alnylam Pharmaceuticals? ↗

April 21, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

April 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗

April 15, 2025

Via Benzinga

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Is Alnylam Pharmaceuticals Gaining or Losing Market Support? ↗

April 04, 2025

Via Benzinga

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

April 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗

March 31, 2025

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗

March 31, 2025

Via Benzinga

FDA Approves Sanofi's Hemophilia Drug ↗

March 31, 2025

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.

Via Benzinga

Competitive Analysis In The ATTR-CM Field ↗

March 30, 2025

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...

Via Talk Markets

Topics Stocks / Equities

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

March 29, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.